Abstract

FORMULATION DESIGN AND IN VITRO CHARACTERIZATION OF TABLET A COMBINATION OF ETODOLAC AND SERRATIOPEPTIDASE

Mangroliya Rohit Kumar*, Dr. Sharma H. K., Ojha Sunil, Dr. Agrawal Amit, Kushwaha R. S. K. and Mishra T. S.

ABSTRACT

The primary object of the present project is to formulate a robust, stable, version of tablet containing an Anti-inflammatory agent (Etodolac) & and Prolytic enzyme (Serratiopeptidase) for the treatment on Osteoarthritis; Rheumatoid arthritis. Etodolac is newly invented NSAID’s it reduce pain and inflammation while Serratiopeptidase reduce swelling & puse formation the combination of both agent helps wound healing process. Combination of Etodolac & serratiopeptidase not available in market so we have to develop it as market need. The objective of the development programmed was to formulate a robust, stable, version of tablet containing 400 mg Etodolac & 15 mg Serratiopeptidase. The drug release mechanism from such a system can be explained by diffusion, dissolution, erosion, surface desorption, combination of diffusion and erosion. In trial 1 Eudragit L-100 (4mg/tab) was used for enteric coating of serratiopeptidase. In trial 2 Eudragit L-100 (8mg/tab) was used for enteric coating of serratiopeptidase. In trial 3 film coating is done on tablets. All physical parameters were found satisfactory but assay of serratiopeptidase part on stability study at 3M 40/75(3 Month at 40°C and 75% Relative Humidity) was found on lower side which moved us to redevelop formulation with a novel touch such as Tab in tab or Inlay tablet.

Keywords: Serratiopeptidase, Eudragit L-100, Etodolac, Anti-inflammatory agent, Prolytic enzyme.